Riccardo Pofi, Elisa Giannetta, Tiziana Feola, Nicola Galea, Federica Barbagallo, Federica Campolo, Roberto Badagliacca, Biagio Barbano, Federica Ciolina, Giuseppe Defeudis, Tiziana Filardi, Franz Sesti, Marianna Minnetti, Carmine D Vizza, Patrizio Pasqualetti, Pierluigi Caboni, Iacopo Carbone, Marco Francone, Carlo Catalano, Paolo Pozzilli, Andrea Lenzi, Mary Anna Venneri, Daniele Gianfrilli, Andrea M Isidori
Cyclic GMP-phosphodiesterase type 5 (PDE5) inhibition has been shown to counteract maladaptive cardiac changes triggered by diabetes in some but not all studies. We performed a single-center, 20-week, double-blind, randomized, placebo-controlled trial (NCT01803828) to assess sex differences in cardiac remodeling after PDE5 inhibition in patients with diabetic cardiomyopathy. A total of 122 men and women (45 to 80 years) with long-duration (>3 years) and well-controlled type 2 diabetes mellitus (T2DM; HbA1c < 86 mmol/mol) were selected according to echocardiographic signs of cardiac remodeling...
June 15, 2022: Science Translational Medicine